Clene reports Q2 EPS (78c) vs ($1.06) last year

Reports Q2 revenue $27k vs $91k last year. “We look forward to engaging with the FDA in our upcoming meeting this quarter focused on the extensive survival data that CNM-Au8 has generated in ALS patients. We are also advancing activities necessary to analyze our NIH-sponsored EAP neurofilament light biomarker data, with results expected in the fourth quarter,” said Rob Etherington, President and CEO of Clene (CLNN). “These meetings and biomarker analyses represent the final steps to our potential submission of an NDA under the accelerated approval pathway for ALS by the end of 2025. Our commitment to the ALS community remains unwavering as we endeavor to develop an impactful therapeutic agent for this devastating disease,” he concluded.